Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab vs nivolumab + ipilimumab vs placebo in stage IV melanoma with no evidence of disease
2014-001167-12Phase 2Completed
- Sponsor
- University of Duisburg-Essen
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing Nivolumab monotherapy, Nivolumab + ipilimumab combination and Double placebo control (3 arms). Primary endpoint: Recurrence-free survival. Started Feb 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-001167-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001167-12.